Andrew A. Harrison

Andrew A. Harrison

Auto-generated profile, based on publicly available information

Andrew A. Harrison

Department of Medicine, University of Otago, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Wallace Chak Sing LauWallace Chak Sing Lau
Wallace Chak Sing Lau
FCFaith Chia
Faith Chia
LDLeonila Dans
Leonila Dans
AHAndrew Harrison
Andrew Harrison
THTsu Yi Hsieh
Tsu Yi Hsieh
SYSwan Sim Yeap
Swan Sim Yeap

1 March 2008 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CMCushla McKinney
Cushla McKinney
MMM E Merriman
M E Merriman
PCP T Chapman
P T Chapman
PGP J Gow
P J Gow
AHA A Harrison
A A Harrison
Tony R. MerrimanTony R. Merriman
Tony R. Merriman
Objective: There is increasing evidence that gene copy-number variation influences phenotypic variation. Chemokine ligand 3-like 1 (CCL3L1) is encoded by a variable copy-number gene, and binds to several pro-inflammatory cytokine receptors, including chemokine receptor 5 (CCR5). Considering lymphocyte recruitment by β-chemokines is a feature of autoimmunity, and that the CCR5Δ32 variant is associated with protection to rheumatoid arthritis (RA), we hypothesised that CCL3L1 copy-number influences susceptibility to RA and type 1 diabetes (T1D). Methods: We measured CCL3L1 copy-number in 1136 RA cases from New Zealand (NZ) and the UK, 252 NZ T1D cases and a total of 1470 controls. All subjects were ancestrally Caucasian. Results: A copy-number higher than 2 (the most common copy number) was a risk factor for RA in the NZ cohort (odds ratio (OR) 1.34, 95% CI 1.08–1.66, p = 0.009) but not the smaller UK RA cohort (OR 1.09, 95% CI 0.75–1.60, p = 0.643). There was evidence for association in the T1D cohort (OR 1.46, 95% CI 0.98–2.20, p = 0.064) and in the combined RA/T1D cohort (OR 1.30, 95% CI 1.00–1.54, p = 0.003). Genetic interaction between CCL3L1 dosage and CCR5 genotype was found; the increased genetic risk conferred by higher CCL3L1 copy-number was ablated by a dysfunctional CCR5 (CCR5Δ32). Conclusions: These data suggest that increased CCL3L1 expression may enhance inflammatory responses and increase the chance of autoimmune disease. Genetic interaction data were consistent with a biologically plausible model; CCR5Δ32 protects against RA and T1D by blocking signalling through the CCR5 pathway, mitigating the pro-inflammatory effects of excess CCL3L1.

3 September 2015 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
Wallace Chak Sing LauWallace Chak Sing Lau
Wallace Chak Sing Lau
FCFaith Chia
Faith Chia
AHAndrew Harrison
Andrew Harrison
THTsu‐Yi Hsieh
Tsu‐Yi Hsieh
RJRahul Jain
Rahul Jain
SYSwan Sim Yeap
Swan Sim Yeap
Aims: Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia‐Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue.Materials and methods: The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia‐Pacific region.Results: Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report.Conclusion: The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia‐Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia‐Pacific for developing guidelines in their respective countries.

21 September 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
APAmanda J. Phipps-Green
Amanda J. Phipps-Green
JHJade E. Hollis-Moffatt
Jade E. Hollis-Moffatt
NDNicola Dalbeth
Nicola Dalbeth
MMMarilyn E. Merriman
Marilyn E. Merriman
RTRuth Topless
Ruth Topless
Tony R. MerrimanTony R. Merriman
Tony R. Merriman
Genetic variation in ABCG2 (rs2231142, Q141K), encoding a uric acid transporter, is associated with gout in diverse populations. The aim of this study was to examine a role for ABCG2 in gout susceptibility in New Zealand Māori, Pacific Island and Caucasian samples. Patients (n = 185, 173 and 214, for Māori, Pacific Island and Caucasian, respectively) satisfied the American College of Rheumatology gout classification criteria. The comparison samples comprised 284, 129 and 562 individuals, respectively, without gout. rs2231142 was genotyped and stratification accounted for using genomic control markers. Association of the minor allele of rs2231142 with gout was observed in the Pacific Island samples (OR = 2.80, PSTRAT < 0.001 after accounting for effects of population structure), but not in the Māori samples (OR = 1.08, PSTRAT= 0.70), with heterogeneity in association evident between the Māori and Pacific Island datasets (PHET = 0.001). A similar dichotomy in association was observed when samples were stratified into Western (Tonga, Samoa, Niue, Tokelau) versus Eastern Polynesian (Māori, Cook Island) origin (OR = 2.59, PSTRAT < 0.001; OR = 1.12, PSTRAT= 0.48, respectively; PHET = 0.005). Association with gout was observed in the Caucasian samples (OR = 2.20, P = 3.2 × 10−8). Unlike SLC2A9, which is a strong risk factor for gout in both Māori and Pacific Island people, ABCG2 rs2231142 has a strong effect only in people of Western Polynesian ancestry. Our results emphasize the need to account for sub-population differences when undertaking biomedical genetic research in a group defined by a geographical region and shared ancestry but characterized by migratory events that create bottlenecks and altered genetic structure in the founder populations.

29 October 2009 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JHJade E. Hollis‐Moffatt
Jade E. Hollis‐Moffatt
XXXin Xu
Xin Xu
NDNicola Dalbeth
Nicola Dalbeth
MMMarilyn E. Merriman
Marilyn E. Merriman
RTRuth Topless
Ruth Topless
Tony R. MerrimanTony R. Merriman
Tony R. Merriman
Objective: To examine the role of genetic variation in the renal urate transporter SLC2A9 in gout in New Zealand sample sets of Māori, Pacific Island, and Caucasian ancestry and to determine if the Māori and Pacific Island samples could be useful for fine‐mapping.Methods: Patients (n= 56 Māori, 69 Pacific Island, and 131 Caucasian) were recruited from rheumatology outpatient clinics and satisfied the American College of Rheumatology criteria for gout. The control samples comprised 125 Māori subjects, 41 Pacific Island subjects, and 568 Caucasian subjects without arthritis. SLC2A9 single‐nucleotide polymorphisms rs16890979 (V253I), rs5028843, rs11942223, and rs12510549 were genotyped (possible etiologic variants in Caucasians).Results: Association of the major allele of rs16890979, rs11942223, and rs5028843 with gout was observed in all sample sets (P = 3.7 × 10−7, 1.6 × 10−6, and 7.6 × 10−5 for rs11942223 in the Māori, Pacific Island, and Caucasian samples, respectively). One 4‐marker haplotype (1/1/2/1; more prevalent in the Māori and Pacific Island control samples) was not observed in a single gout case.Conclusion: Our data confirm a role of SLC2A9 in gout susceptibility in a New Zealand Caucasian sample set, with the effect on risk (odds ratio >2.0) greater than previous estimates. We also demonstrate association of SLC2A9 with gout in samples of Māori and Pacific Island ancestry and a consistent pattern of haplotype association. The presence of both alleles of rs16890979 on susceptibility and protective haplotypes in the Māori and Pacific Island sample is evidence against a role for this nonsynonymous variant as the sole etiologic agent. More extensive linkage disequilibrium in Māori and Pacific Island samples suggests that Caucasian samples may be more useful for fine‐mapping.

1 September 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ZLZhixiu Li
Zhixiu Li
XWXin Wu
Xin Wu
PLPaul J Leo
Paul J Leo
EGErika De Guzman
Erika De Guzman
NANurullah Akkoc
Nurullah Akkoc
MBMatthew A Brown
Matthew A Brown
Objective We sought to test the hypothesis that Polygenic Risk Scores (PRSs) have strong capacity to discriminate cases of ankylosing spondylitis (AS) from healthy controls and individuals in the community with chronic back pain. Methods PRSs were developed and validated in individuals of European and East Asian ethnicity, using data from genome-wide association studies in 15 585 AS cases and 20 452 controls. The discriminatory values of PRSs in these populations were compared with other widely used diagnostic tests, including C-reactive protein (CRP), HLA-B27 and sacroiliac MRI. Results In people of European descent, PRS had high discriminatory capacity with area under the curve (AUC) in receiver operator characteristic analysis of 0.924. This was significantly better than for HLA-B27 testing alone (AUC=0.869), MRI (AUC=0.885) or C-reactive protein (AUC=0.700). PRS developed and validated in individuals of East Asian descent performed similarly (AUC=0.948). Assuming a prior probability of AS of 10% such as in patients with chronic back pain under 45 years of age, compared with HLA-B27 testing alone, PRS provides higher positive values for 35% of patients and negative predictive values for 67.5% of patients. For PRS, in people of European descent, the maximum positive predictive value was 78.2% and negative predictive value was 100%, whereas for HLA-B27, these values were 51.9% and 97.9%, respectively. Conclusions PRS have higher discriminatory capacity for AS than CRP, sacroiliac MRI or HLA-B27 status alone. For optimal performance, PRS should be developed for use in the specific ethnic groups to which they are to be applied.